Difficulties in the differential diagnosis of granulomatous interstitial nephritis

Granulomatous tubulointerstitial nephritis (GTIN) is the rarest form of acute tubulointerstitial nephritis (ATIN) and, therefore, may present with acute kidney injury (AKI). GTIN accounts for only 0.5-0.9% of cases in the spectrum of native kidney biopsies, 0.6% in graft biopsies, and 6% in nephrobiopsies in interstitial nephritis. Identification of this morphological variant of ATIN obliges the physician to conduct a differential diagnosis between diseases characterized by the development of granulomatous inflammation in different organs, which is often associated with significant difficulties. The presented observation of GTIN in a 57-year-old patient without a history of chronic kidney disease (CKD), with newly diagnosed type 2 diabetes mellitus and developed AKI after the start of therapy with modern hypoglycemic drugs from the group of sodium-glucose cotransporter-2 inhibitors (iSGLT-2) - dapagliflozin and the glucagon-like peptide-1 receptor agonist (GLP-1 RA) - semaglutide examination which led to the diagnosis of sarcoidosis with lesions of the lungs, intrathoracic and intra-abdominal lymph nodes, illustrates the complexity of the diagnostic search in such cases. The granulomas found during the morphological examination of the kidney biopsy did not have signs of caseous necrosis and were combined with diffused eosinophilic infiltration of the renal interstitium, which made it even more difficult to differentiate between GTIN of drug-induced etiology and sarcoidosis kidney damage. The key feature of the disease was the unresolved AKI after the discontinuation of antidiabetic drugs by the patient, and newly diagnosed sarcoidosis, both of which served as the reason for determining the leading cause of GTIN in the presence of two likely triggers - drug-induced kidney injury and systemic granulomatous disease. A thorough analysis of the clinical and morphological manifestations of the disease led to the conclusion that granulomatous lesions of the interstitium have combined genesis. The features of the course of GTIN in sarcoidosis and drug-induced kidney injury are also discussed. It is noted that the presented observation is the first description of the GTIN case when using a combination of drugs from the iSGLT-2 and GLP-1 RA groups. In connection with the simultaneous appearance of AKI and signs of sarcoidosis, the possibility of developing a drug-induced sarcoidosis-like reaction is discussed. Difficulties in isolating the leading factor in the development of the disease, in this case, did not prevent the initiation of pathogenetic therapy with systemic corticosteroids with the achievement of a rapid effect: a decrease in blood creatinine and a positive clinical and radiological dynamics of the pulmonary process were noted.

лекарственный тубулоинтерстициальный нефрит, гранулематозный тубулоинтерстициальный нефрит, острое повреждение почек, иНГЛТТ-2, агонисты рецепторов ГПП-1, саркоидоз, лекарственно-индуцированная саркоидоз-подобная реакция, drug-induced tubulointerstitial nephritis, granulomatous tubulointerstitial nephritis, acute kidney injury, sarcoidosis, iSGLT-2, GLP-1 receptor agonist, Drug-Induced Sarcoidosis-Like Reactions

1. Shah K.K., Pritt B.S., Alexander M.P. Histopathologic review of granulomatous inflammation. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 2017. 7:1-12. http://dx.doi.org/10.1016/j.jctube.2017.02.001

2. Aleckovic-Halilovic M., Nel D., Woywodt A. Granulomatous interstitial nephritis: a chameleon in a globalized world. Clinical Kidney Journal. 2015. 8(5):511-515. doi: 10.1093/ckj/sfv092

3. Shah S., Carter-Monroe N., Atta M.G. Granulomatous interstitial nephritis. Clin Kidney J. 2015. 8(5):516-523 doi: 10.1093/ckj/sfv053

4. Joss N., Morris S., Young B. et al. Granulomatous interstitial nephritis. Clin J Am Soc Nephrol. 2007. 2 (2):222-230. doi: 10.2215/CJN.01790506

5. Janssen U., Naderi S., Amann K. Idiopathic granulomatous interstitial nephritis and isolated renal sarcoidosis: Two diagnoses of exclusion. SAGE Open Medicine. 2021. 9:1-6. doi: 10.1177/20503121211038470

6. Figueiredo A.C., Rodrigues L., Sousa V. et al. Granulomatous interstitial nephritis: a rare diagnosis with an overlooked culprit. BMJ Case Rep. 2019. 12(8):e229159. doi: 10.1136/bcr-2018-229159

7. Bergner R., Lőffler C. Renal sarcoidosis: approach to diagnosis and management. Curr Opin Pulm Med. 2018. 24:513-520. doi: 10.1097/MCP.0000000000000504

8. Gorsane I., Zammouri A., Hajji M. et al. Renal involvement in sarcoidosis: Prognostic and predictive factors. Nephrol Ther. 2022. 18(1):52-58. doi: 10.1016/j.nephro.2021.08.001

9. Robson M.G., Banerjee D., Hopster D. et al. Seven cases of granulomatous interstitial nephritis in the absence of extrarenal sarcoid. Nephrol Dial Transplant. 2003. 18:280-284 doi: 10.1093/ndt/18.2.280

10. Leehey D.J., Rahman M.A., Borys E. et al. Acute Kidney Injury Associated With Semaglutide. Kidney Med. 2021. 3(2):282-285. doi: 10.1016/j.xkme.2020.10.008

11. Advera Health Analytics, Inc. (2020) “FAERS Adverse Event, Acute Kidney Injury, Glucagon-like peptide-1 (GLP-1) Analogues Classification Comparison Report.” Evidex. https://www.adverahealth. com/explorer/#/druggroup/drugclass/A10BJ/pivot/ROR?event id=10069339. Accessed April 24, 2020.

12. Sharma T., Paixao R., Villabona C. GLP-1 agonist associated acute kidney injury: A case report and review. Diabetes & Metabolism Volume. 2019. 45(5):489-491. doi: 10.1016/j.diabet.2017.12.002

13. Pratley R.E., Aroda V.R., Lingvay I. et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The Lancet Diabetes & Endocrinology. 2018. 6(4):275-286. doi: 10.1016/S2213-8587(18)30024-X

14. Phadke G., Kaushal A., Tolan D.R. et al. Osmotic nephrosis and acute kidney injury associated with SGLT2 inhibitor use: a case report. Am J Kidney Dis. 2020. 76:144-147. doi: 10.1053/j.ajkd.2020.01.015

15. Pleros C., Stamataki E., Papadaki A. et al. Dapagliflozin as a cause of acute tubular necrosis with heavy consequences: a case report. CEN Case Rep. 2018. 7:17-20, doi: 10.1007/s13730-017-0283-0

16. Konta Y., Saito E., Sato K. et al. Tubulointerstitial Nephritis after Using a Sodium-glucose Cotransporter 2 Inhibitor. Intern Med. 2022. 61(21):3239-3243. doi: 10.2169 /internalmedicine.9011-21

17. Gariani K., de Seigneux S., Moll S. Acute Interstitial Nephritis After Treatment With Liraglutide. Originally published online December 5, 2013. 2014 by the National Kidney Foundation, Inc. http://dx.doi.org/10.1053/j.ajkd.2013.10.057

18. Chopra A., Nautiyal A., Kalkanis A. et al. Drug-Induced Sarcoidosis-Like Reactions. Chest. 2018. 154(3):664-677. doi: 10.1016/j.chest.2018.03.056

19. Cohen Aubart F., Lhote R., Amoura A. et al. Drug-induced sarcoidosis: an overview of the WHO pharmacovigilance database. J Intern Med 2020. 288:356-362. doi: 10.1111/joim.12991

20. Miedema J., Nunes H. Drug-induced sarcoidosis-like reactions. Curr Opin Pulm Med. 2021. 27:439-447. doi:10.1097/MCP.0000000000000800